Systemic Juvenile Idiopathic Arthritis Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled Parallel Trial of Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody by Single Subcutaneous Injection in Healthy Subjects
This study is Safety, Tolerability and Pharmacokinetic of Recombinant anti-IL-1β Humanized Monoclonal Antibody injection in Healthy Subjects. Pharmacokinetics, Pharmacodynamics and Anti-drug antibody (ADA) data will be collected; Drug safety, tolerability and immunogenicity for healthy subjects will be evaluated.
This study is a randomized, double-blind, placebo-controlled parallel trial of safety, tolerability and pharmacokinetic of Recombinant anti-IL-1β Humanized Monoclonal Antibody by single subcutaneous injection with five different doses in healthy subjects. There are 5 groups as follows: 0.03mg/kg (S1), 1.0mg/kg (S2), 3.0mg/kg (S3), 6.0mg/kg (S4) and 10.0mg/kg (S5); and 2 subjects were included in the S1 group (both received study drugs); 8 subjects were included in each of the S2 ~ S5 groups (of which 6 received study drugs and 2 received placebo). In each group, two subjects were sentinels (1 received the study drug and 1 placebo). Pharmacokinetics, Pharmacodynamics and Anti-drug antibody (ADA) data will be collected; Drug safety, tolerability and immunogenicity for healthy subjects will be evaluated. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00891046 -
An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.
|
Phase 3 | |
| Completed |
NCT01304420 -
Ultrasonography in Juvenile Idiopathic Arthritis
|
Phase 0 | |
| Completed |
NCT02334748 -
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
|
Phase 3 | |
| Completed |
NCT01803321 -
Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
|
Phase 1 | |
| Completed |
NCT00144664 -
Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
|
Phase 3 | |
| Completed |
NCT02396212 -
Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA
|
Phase 3 | |
| Completed |
NCT00144599 -
Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
|
Phase 3 | |
| Terminated |
NCT00886769 -
Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)
|
Phase 3 | |
| Completed |
NCT00144612 -
Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
|
Phase 3 | |
| Withdrawn |
NCT01676948 -
An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
|
Phase 3 | |
| Recruiting |
NCT04088396 -
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA
|
Phase 3 |